Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis [2]

Leukemia

Volumn 16, Issue 10, 2002, Pages 2160-2161

  Ohyashiki, K ^a   Kuriyama, Y ^a   Nakajima, A ^a   Tauchi, T ^a   Ito, Y ^a   Miyazawa, K ^a   Kimura, Y ^a   Serizawa, H ^a   Ebihara, Y ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; HYDROXYUREA; IMATINIB;

ADULT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; LETTER; LEUKOCYTE COUNT; LIVER BIOPSY; LIVER NECROSIS; LIVER TOXICITY; PRIORITY JOURNAL; RASH; VIRUS HEPATITIS;

EID: 0036796973     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402702     Document Type: Letter

References (8)

1. Kantarjian HM, Talpaz M. Imatinib mesylate: clinical results in Philadephia chromosome-positive leukemias. Semin Oncol 2001; 5: 9-18.
2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
3. Goldman JM, Druker BJ. Chronic myeloid leukamia: current treatment options. Blood 2001; 98: 2039-2042.
4. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, Talpaz M, Druker B. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
5. Mauro MJ, O'Dwyer M, Heinrich MC, Druker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002; 20:325-334.
6. Burton C, Azzi A, Kerridge I. Adverse events after imatinib mesylate therapy. N Engl J Med 2002; 346: 713.
7. Elliot MA, Mesa RA, Tefferi A. Adverse events after imatinib mesylate therapy. N Engl J Med 2002; 346: 713.
8. O'Brien SG, Peng B, Dutrix C, Mehring G, Milosavljev S, Capdeville R, Fischer T. A pharmacokinetic interaction of Glivec and simvastatin, a cytochrome 3A4 substrate, in a patients with chronic myeloid leukemia. Blood 2001;98 (Suppl.) :141a (593).